

Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities



Specialized research sites with multi-therapeutic expertise play a crucial role in successfully bringing new drugs and treatments to market. They offer end-to-end support services handling patient recruitment, regulatory compliance, and data collection within compressed timelines. These sites ensure efficient trial execution and their expertise is valuable for sponsors navigating the complexities of the clinical development process. Clinical research sites' contributions are instrumental in advancing public health on a global scale.

Accel Research Sites Network ("Accel") is a highly regarded research site network dedicated to advancing clinical research and helping novel medicines reach the patients who need them for nearly 25 years.

With a highly attractive portfolio of research sites, they specialize in streamlining the clinical trial process, expediting the development of life-saving treatments. With 2,500+ completed trials and 22 research sites in the Southeast region of the US, Accel is a leader in medical research. This market leadership position made Accel the ideal acquisition for Alcanza to expand its clinical trial site network and overall capabilities.

Crosstree's expertise in the clinical trial site space and deep understanding of Accel's unique value proposition helped the firm advise Accel in identifying Alcanza as the ideal transaction partner to accelerate the company's growth expand their foothold in the Southeast region of the US.

Crosstree helps clients by leveraging deep market expertise to identify the ideal partner that will maximize synergies, and position the client to maximize its value.

ABOUT ACCEL RESEARCH SITES NETWORK



Accel Research Sites Network was founded in 1998 and has developed an outstanding reputation over its 24-year history. The company has conducted more than 2,500 trials with 50,000+ patients establishing themselves as a leader in the clinical research space. Today, Accel has 22 research sites in Florida, Georgia, and Alabama that bring families, healthcare providers, and researchers together to deliver cutting-edge treatment options.

ABOUT ALCANZA



Alcanza Clinical Research is an integrated network of research facilities dedicated to reducing barriers to clinical research participation, especially in underrepresented patient populations. The network is comprised of 17 dedicated research units and 16 additional sites integrated within specialty clinics. These facilities are strategically located across the Southeast, Northeast, and Midwest regions of the United States. Alcanza sites support studies that span all clinical trial phases and major therapeutic areas.

Alcanza is a portfolio company of Martis Capital.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JASON LAYTON

Director

jason.layton@crosstreecapital.com

813-578-7109